Long COVID outcomes in an asthmatic cohort and its implications for asthma control

Abstract

•COVID-19 infection had not an influence on asthma outcomes.•There is a potential protection of T2-asthma against acute COVID infection.•The severity of asthma was associated with worse long-term outcomes of COVID-19. COVID-19 disease is an infectious entity caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that has spread throughout the world [[1]Borobia A.M. Carcas A.J. Arnalich F. Álvarez-Sala R. Monserrat-Villatoro J. Quintana M. et al.A cohort of patients with COVID-19 in a major teaching hospital in Europe.J. Clin. Med. 2020; 9: E1733Crossref PubMed Google Scholar]. Some people who have recovered from the acute phase of COVID-19 have symptoms for weeks or months much longer than expected (long COVID). Several long-term symptoms, such as dyspnea, chronic fatigue, chest pain, or cognitive impairment, may persist after SARS-CoV-2 infection [[2]Song W.-J. Hui C.K.M. Hull J.H. Birring S.S. McGarvey L. Mazzone S.B. et al.Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses.Lancet Respir. Med. 2021; 9: 533-544Abstract Full Text Full Text PDF PubMed Google Scholar]. Asthma is a chronic inflammatory disease in the airways that affects over 300 million people [[3]Howell D. Verma H. Ho K.S. Narasimhan B. Steiger D. Rogers L. Asthma and COVID-19: lessons learned and questions that remain.Expet Rev. Respir. Med. 2021; 15: 1377-1386Crossref PubMed Scopus (1) Google Scholar]. Most studies worldwide do not consider asthma as a comorbidity associated with the risk of severe COVID-19 infection [[3]Howell D. Verma H. Ho K.S. Narasimhan B. Steiger D. Rogers L. Asthma and COVID-19: lessons learned and questions that remain.Expet Rev. Respir. Med. 2021; 15: 1377-1386Crossref PubMed Scopus (1) Google Scholar], particularly for allergic asthma [[4]Habernau Mena A. García-Moguel I. Vazquez de la Torre Gaspar M. Mugica V. Alvarado Izquierdo M.I. Jimenez Blanco M.A. et al.COVID-19 course in allergic asthma patients: a Spanish cohort analysis.J. Asthma Allergy. 2022; 15: 257-264Crossref PubMed Scopus (1) Google Scholar]. However, a recent meta-analysis described being young and obese as risks factors [[5]Choi J.H. Choi S.H. Yun K.W. Risk factors for severe COVID-19 in children: a systematic review and meta-analysis.J. Kor. Med. Sci. 2022; 37: e35Crossref PubMed Google Scholar]. It has been hypothesized that there could be a protective factor for eosinophils and T2 cytokines in COVID-19 disease. Warner et al. [[6]Warner J.O. Warner J.A. Munblit D. Hypotheses to explain the associations between asthma and the consequences of COVID-19 infection.Clin. Exp. Allergy. 2022; 52: 7-9Crossref PubMed Scopus (7) Google Scholar] and Muñoz et al. [[7]Muñoz X. Pilia F. Ojanguren I. Romero-Mesones C. Cruz M.J. Is asthma a risk factor for COVID-19? Are phenotypes important?.ERJ Open Res. 2021; 7 (00216-2020)Crossref PubMed Scopus (12) Google Scholar] pointed out the protective effect of eosinophils against COVID-19. Eosinophils have antiviral properties such as expression of Toll-Like Receptor-7 that recognizes RNA viruses such as SARS-COV2, antigen presentation function, secretion of Th1 cytokines such as interferon gamma and IL-12, and generation of superoxide and nitric oxide [[6]Warner J.O. Warner J.A. Munblit D. Hypotheses to explain the associations between asthma and the consequences of COVID-19 infection.Clin. Exp. Allergy. 2022; 52: 7-9Crossref PubMed Scopus (7) Google Scholar]. Airway eosinophils, however, have an inflammation-regulating activity that could protect against hyperinflammatory conditions in COVID-19 infection [[6]Warner J.O. Warner J.A. Munblit D. Hypotheses to explain the associations between asthma and the consequences of COVID-19 infection.Clin. Exp. Allergy. 2022; 52: 7-9Crossref PubMed Scopus (7) Google Scholar]. Furthermore, innate immune responses to viral respiratory infections (e.g. COVID-19) are associated with innate lymphoid cells type 2 (ILC2) that release alarmins such as IL-23, IL-33 and thymic stromal lymphopoetin (TSLP) that fight COVID-19 infection. ILC2 release IL-4 and IL-5 cytokines that induce eosinophil proliferation and maturation [[6]Warner J.O. Warner J.A. Munblit D. Hypotheses to explain the associations between asthma and the consequences of COVID-19 infection.Clin. Exp. Allergy. 2022; 52: 7-9Crossref PubMed Scopus (7) Google Scholar]. Notwithstanding, there is a lack of information on post-COVID symptoms in patients with asthma in the long-term [[7]Muñoz X. Pilia F. Ojanguren I. Romero-Mesones C. Cruz M.J. Is asthma a risk factor for COVID-19? Are phenotypes important?.ERJ Open Res. 2021; 7 (00216-2020)Crossref PubMed Scopus (12) Google Scholar]. The aim of this study was to assess the long COVID outcomes after six to twelve months of an asthma population. We also attempted to identify clinical features during the acute episode of COVID-19 and their potential implications for asthma outcomes. This is a one single-center, consecutive descriptive observational retrospective study. La Paz University Hospital is one of the largest hospitals in this region and has developed one of the largest cohorts in Europe with more than 3500 patients collected during the pandemic [[1]Borobia A.M. Carcas A.J. Arnalich F. Álvarez-Sala R. Monserrat-Villatoro J. Quintana M. et al.A cohort of patients with COVID-19 in a major teaching hospital in Europe.J. Clin. Med. 2020; 9: E1733Crossref PubMed Google Scholar]. We collected demographic, clinical and laboratory data from the medical history. The inclusion criteria were consecutive asthmatic patients older than 18 years-old admitted in Emergency Department in our hospital that presented firmly established COVID-19 infection (173 patients) confirmed by polymerase chain reaction during the first and second COVID-19 waves (March–December 2020), no patients were vaccinated at this point. The protocol was approved by local regulatory ethics committee (ethics committee La Paz University Hospital; Madrid, Spain (PI-4336), and respected the ethical principles of the Declaration of Helsinki. We employed a modified version of the electronic case record form (eCRF) for severe acute respiratory infections, developed by the World Health Organization/International Severe Acute Respiratory and Emerging Infection Consortium [[8]Novel coronaviris (nCoV) acute respiratory infection clinical characterisation data tools. nCoV case records form version 1.3. 24.https://media.tghn.org/medialibrary/2020/03/ISARIC_COVID19_CRF_V1.3_24Feb2020.pdfDate accessed: September 28, 2022Google Scholar]. Our eCRF includes 94 variables, grouped into demographics, asthma medical history, COVID-19 infection clinical history, and post-COVID-19 clinical history. We collected the clinical data directly extracting the information by a manual and individual review of the patients’ electronic clinical records, including the clinical notes (DXC–HCIS– Healthcare Information System). The data collection effort was conducted by a volunteer team of resident doctors and medical doctors from La Paz University Hospital. Demographics data included sex, age, comorbidities (smoking habit, COPD, obesity (body mass index ≥30), obstructive-sleep-apnoea syndrome, gastro-oesophageal reflux, chronic rhinosinusitis with nasal polyps, congestive heart failure, anxiety and depression) blood eosinophils, and immunoglobulin E (IgE). We classified patients as having T2 or non-T2-asthma according to the 2021 Global Initiative for Asthma guidelines [[9]Reddel H.K. Bacharier L.B. Bateman E.D. Brightling C.E. Brusselle G.G. Buhl R. et al.Global initiative for asthma (GINA) strategy 2021 - executive summary and rationale for key changes.Am. J. Respir. Crit. Care Med. 2022; 205: 17-35Crossref PubMed Scopus (57) Google Scholar]. We collected previous asthma treatment, including inhaled therapy, use of oral corticosteroids (OCS), biological treatment, azithromycin and antileukotrienes. Pre-COVID-19 and post-COVID-19 asthma control measured by asthma control test (ACT) and number of previous exacerbations in one year and after the episode, were registered. Pre-COVID-19 and Post-COVID-19 pulmonary lung function, blood eosinophils, and IgE were also studied. For the acute COVID-19, the presence of thoracic symptoms as chest pain, cough, expectoration, dyspnea, anosmia and ageusia were recorded and evaluated after 6 and 12 months post-disease. The presence of pneumonia, thromboembolism, need of hospitalization, admission to intensive care unit (ICU) or intermediate respiratory care units (IRCU) and mortality were also considered. Treatment during the acute episode was also analyzed. We also collected the post-COVID-19 symptoms (chest pain, cough, expectoration, dyspnea). Both asthma control test (ACT) and the number of exacerbations during this period were collected. Other variables included were the treatment post-COVID-19, including inhaled therapy, use of OCS, biologic treatment and pulmonary lung function. We analyzed qualitative data with absolute frequencies and percentages and quantitative data in mean and standard deviation, or median and ranks. The Kolmogorov-Smirnov test evaluated normality in continuous data. The chi-squared test, or the exact Fisher test, studied the association between categorical variables. The Mann-Whitney U test studied the association between categorical and continuous variables. We have applied logistic regression with multivariant regression models in order to assess the risk factors to have some acute and long-term outcomes. All statistical tests were bilateral and significant if p < 0.05. We analyzed data with SAS 9.3 program (SAS-Institute,Cary,NC,USA). The average age was 55 years, 67% were women, 22% were smokers. 60.7% had T2-asthma. We did not discontinue previous treatments with OCS, inhalers and omalizumab during COVID-19 disease. Table-1 lists baseline characteristics of 173 patients included.Table 1Baseline characteristics.All participants (n = 173)Age, years55.53 ± 18.2 (n = 173)Gender Men56/173 (32.0%)T2 asthma105/171 (60.7%)Smoking habit39/172 (22.5%)Pack year index11.7 ± 17.9 (n = 38)Hospitalizations116/173 (67.1%)Mortality at 12 months19/173 (11.0%)ICU admission9/119 (5.2%)COVID acute pneumonia105/171 (60.7%)Pre-COVID ACT23.8 ± 2.6 (n = 15)Pre-COVID Number of exacerbations0.16 ± 0.54 (n = 138)Pre-COVID FEV1 (%)87.89 ± 27.03 (n = 53)Pre-COVID asthma treatment ICS23/168 (13.3%) ICS + LABA117/172 (67.6%) LAMA25/172 (14.5%) SABA94/172 (54.3%) Antileukotrienes28/172 (16.2%) Azithromycin1/173 (0.6%) Omalizumab2/172 (1.2%) OCS8/172 (4.6%)Symptoms during COVID-19 Dyspnea130/172 (75.1%) Chest pain45/172 (26.0%) Cough139/170 (80.3%) Wheezing19/165 (11.0%) Anosmia23/172 (13.3%) Ageusia26/172 (15.0%)Co-existing disordersObesity30/173 (17.3%)COPD13/172 (7.5%)Rhinosinusitis44/173 (25.4%)OSA14/173 (8.1%)ACT: asthma control test; COPD: chronic obstructive pulmonary disease; FEV1: Forced expiratory volume in 1 s; ICU: intensive care unit; ICS: inhaled corticosteroids; LABA: long-acting beta agonists; LAMA: long-acting muscarinic antagonist; OCS: Oral systemic corticosteroid; OSA: obstructive sleep apnoea; SABA: short-acting beta agonists. Open table in a new tab ACT: asthma control test; COPD: chronic obstructive pulmonary disease; FEV1: Forced expiratory volume in 1 s; ICU: intensive care unit; ICS: inhaled corticosteroids; LABA: long-acting beta agonists; LAMA: long-acting muscarinic antagonist; OCS: Oral systemic corticosteroid; OSA: obstructive sleep apnoea; SABA: short-acting beta agonists. Mortality at 12 months was 11%. 67% of patients suffered hospitalization and 5% was admitted to ICU. Pneumonia was present in 60% of patients diagnosed with thoracic X-ray or computerized tomography. During COVID-19 disease, 75% of patients suffered dyspnea, 80% cough, 26% chest pain, 15% ageusia, 13% anosmia and 11% wheezing. After a univariant model study, we found a significant association between COVID-19 pneumonia and male patients (odds ratio-OR = 2.828, p = 0.005), current smokers (OR = 2.568, p = 0.024), use of ICS + LABA pre-COVID-19 disease (OR = 3.119, p = 0.001) (table-2). COVID pneumonia was found as a risk factor for chest pain after 6–12 months post-COVID (OR = 5.625, p = 0.01) (Table 2). After a multivariant regression model study, we found a significant association between COVID-19 pneumonia and male patients (p = 0.02) and chest pain after 6–12 months (p = 0.019) (Table 2).Table 2Univariant and multivariant model study.COVID ACUTE PNEUMONIAp-valueORCI 95%Gender0.005 - Men2.8281.375–5.813 - WomenCurrent smokers0.0242.5681.130–5.836Obesity (BMI>30)0.618T2 asthma0.536Pre-COVID ICS treatment0.557Pre-COVID ICS + LABA treatment0.0013.1191.597–6.092Pre-COVID OCS treatment0.153Dyspnea 6–12 months post-COVID0.645Chest pain 6–12 months post-COVID0.0105.6251.503–21.054Cough 6–12 months post-COVID0.774Thromboembolism post-COVID0.421Eosinophilic asthma0.06HOSPITALIZATIONp-valueORCI 95%Gender0.047 - Men2.0001.008–3.967 - WomenCurrent smokers0.0014.8031.887–12.224Obesity (BMI >30)0.054T2 asthma0.0020.3200.153–0.669Pre-COVID ICS treatment0.0060.2720.108–0.686Pre-COVID ICS + LABA treatment0.0022.7931.443–5.404Pre-COVID OCS0.145Dyspnea 6–12 months post-COVID0.411Chest pain 6–12 months post-COVID0.415Cough 6–12 months post-COVID0.665Thromboembolism post-COVID0.830Eosinophilic asthma0.0221.0031.000–1.005BMI: body mass index; CI: confidence interval; ICS: inhaled corticosteroids; LABA: long-acting beta agonists; OCS: oral systemic corticosteroids; OR=Odds ratio. Open table in a new tab BMI: body mass index; CI: confidence interval; ICS: inhaled corticosteroids; LABA: long-acting beta agonists; OCS: oral systemic corticosteroids; OR=Odds ratio. A lower risk of hospitalization was present in patients who suffered T2-asthma (OR = 0.32, p = 0.002) and were treated previously with ICS (OR = 0.272, p = 0.006) (table-2). A higher risk of hospitalization was found in males (OR = 2, p = 0.047), current smokers (OR = 4.803, p = 0.001), and patients treated previously with ICS + LABA (OR = 2.793, p = 0.002). Multivariant regression model found a significant association between hospitalization and smoking (p = 0.045), pre-COVID ICS treatment (p = 0.007), pre-COVID ICS + LABA treatment (p = 0.014) and eosinophilic asthma (p = 0.032) (table-2). After a multivariate regression analysis, we found no association between ICU admission and baseline characteristics (sex, obesity, T2 asthma, ICS pre-COVID-19, ICS + LABA pre-COVID-19, OCS pre-COVID-19). We also studied the association between ICU admission and dyspnea, chest pain and cough after 6–12 months, finding no significant associations. Long-COVID outcomes were also studied at 12 months, dyspnea was present in 52 patients (30%), chest pain in 21 patients (12%) and cough in 21 patients (12%) (table-3). Mean asthma control test (ACT) after 12 months post-COVID was 21.6 ± 4.36, the average number of exacerbations was 0.12 ± 0.435, FEV1 12 months post-COVID was 83.15% ± 21.23. We applied univariant and multivariant regression logistic models to different outcomes after 12 months post-COVID. Dyspnea, cough and corticosteroid requirement after 12 months were not statistically significant. However, chest pain at 12 months post-COVID was less prevalent in T2 asthma (OR = 0.319, p = 0.044) (table-3). There was also a lower necessity of LAMA in T2 asthmatic patients (OR = 0.122, p = 0.008) (table-3).Table 3Long-COVID outcomes.Dyspnea 12 months post-COVID52 (30.1%)Chest pain 12 months post-COVID21 (12.1%)Cough 12 months post-COVID21 (12.1%)ACT 12 months post-COVID21.6 ± 4.36Number of exacerbations 12 months post-COVID0.12 ± 0.435FEV1 12 months post-COVID83.15% ± 21.23Univariant and multivariant regression logistic modelDyspnea at 12 months Post-COVIDp-valueORCI 95%Gender0.225 - Men - WomenCurrent smokers0.437Obesity (BMI>30)0.262T2 asthma0.324Pre-COVID ICS treatment0.123Pre-COVID ICS + LABA treatment0.836Pre-COVID OCS treatment0.606Eosinophilic asthma0.342Chest pain at 12 months Post-COVIDp-valueORCI 95%Gender0.964 - Men - WomenCurrent smokers0.088Obesity (BMI>30)0.505T2 asthma0.0440.3190.105–0.968Pre-COVID ICS treatment0.416Pre-COVID ICS + LABA treatment0.310Pre-COVID OCS treatment0.999Eosinophilic asthma0.572LAMA necessity 12 months post-COVIDp-valueORCI 95%Gender0.314 - Men - WomenCurrent smokers0.067Obesity (BMI>30)0.999T2 asthma0.0080.1220.026–0.581Pre-COVID ICS treatment0.773Pre-COVID ICS + LABA treatment0.404Pre-COVID OCS treatment0.00513.82.192–86.877Eosinophilic asthma0.995ACT: asthma control test; BMI: body mass index; CI: confidence interval; ICS: inhaled corticosteroids; LABA: long-acting beta agonists; LAMA: long-acting muscarinic antagonist; OCS: oral systemic corticosteroids; OR: odds ratio. Open table in a new tab ACT: asthma control test; BMI: body mass index; CI: confidence interval; ICS: inhaled corticosteroids; LABA: long-acting beta agonists; LAMA: long-acting muscarinic antagonist; OCS: oral systemic corticosteroids; OR: odds ratio. The findings observed in this study help us better understand post-acute COVID-19 complications in patients with asthma. Patients with T2-asthma had less chest pain after 12 months post-COVID (OR = 0.319) (table-3). These results are consistent with previous studies, suggesting the potential protection of T2-asthma against acute COVID infection [8Novel coronaviris (nCoV) acute respiratory infection clinical characterisation data tools. nCoV case records form version 1.3. 24.https://media.tghn.org/medialibrary/2020/03/ISARIC_COVID19_CRF_V1.3_24Feb2020.pdfDate accessed: September 28, 2022Google Scholar, 9Reddel H.K. Bacharier L.B. Bateman E.D. Brightling C.E. Brusselle G.G. Buhl R. et al.Global initiative for asthma (GINA) strategy 2021 - executive summary and rationale for key changes.Am. J. Respir. Crit. Care Med. 2022; 205: 17-35Crossref PubMed Scopus (57) Google Scholar, 10Fernández-de-Las-Peñas C. Torres-Macho J. Velasco-Arribas M. Arias-Navalón J.A. Guijarro C. Hernández-Barrera V. et al.Similar prevalence of long-term post-COVID symptoms in patients with asthma: a case-control study.J. Infect. 2021; 83: 237-279Google Scholar, 11Palmon P.A. Jackson D.J. Denlinger L.C. COVID-19 infections and asthma.J. Allergy Clin. Immunol. Pract. 2022; 10: 658-663Abstract Full Text Full Text PDF PubMed Scopus (6) Google Scholar]. Viral infections clearly affect asthma outcomes [[3]Howell D. Verma H. Ho K.S. Narasimhan B. Steiger D. Rogers L. Asthma and COVID-19: lessons learned and questions that remain.Expet Rev. Respir. Med. 2021; 15: 1377-1386Crossref PubMed Scopus (1) Google Scholar,[8]Novel coronaviris (nCoV) acute respiratory infection clinical characterisation data tools. nCoV case records form version 1.3. 24.https://media.tghn.org/medialibrary/2020/03/ISARIC_COVID19_CRF_V1.3_24Feb2020.pdfDate accessed: September 28, 2022Google Scholar,[11]Palmon P.A. Jackson D.J. Denlinger L.C. COVID-19 infections and asthma.J. Allergy Clin. Immunol. Pract. 2022; 10: 658-663Abstract Full Text Full Text PDF PubMed Scopus (6) Google Scholar]. Interestingly, and consistent with previous papers, we have not found that COVID-19 infection had an influence on asthma outcomes at the time of observation in our investigation. Exacerbations, asthma control (measured by ACT), and lung function parameters appeared to be unaffected by COVID-19, at least in most patients (table-3). Unfortunately, we could not perform spirometry on all the study patients because of the pandemic situation. Given that the severity of acute COVID-19 was associated with the development of worse long-term outcomes of COVID-19, it is noteworthy that we found an increased risk of pneumonia in men (OR = 2.828), smokers (OR = 2.568) and subjects previously treated with ICS + LABA (OR = 3.119), it was confirmed by multivariant regression model) (table-2). In line with these findings, we have also observed a higher risk of hospitalization among patients with the same clinical characteristics: men (OR = 2), smokers (OR = 4.803) and treated with ICS + LABA (OR = 2.793). We found less risk in patients previously treated with ICS alone (OR = 0.272) than with an ICS + LABA combination (OR = 2.793), probably explained by severity of asthma in the acute phase of COVID-19, since more severe asthma has been associated with a worse prognosis [[11]Palmon P.A. Jackson D.J. Denlinger L.C. COVID-19 infections and asthma.J. Allergy Clin. Immunol. Pract. 2022; 10: 658-663Abstract Full Text Full Text PDF PubMed Scopus (6) Google Scholar]. In contrast, and, as expected, T2-asthma patients had a lower risk of acute SARS-CoV-2 pneumonia (OR = 0.320), which probably influenced the clinical presentation of prolonged COVID. The major drawback of this study is its retrospective design, in several waves of evolution of the pandemic. These circumstances make up the major limitation of the study, which is the absence of a prospective design that allows greater validation of these results. We also believe that some trends seen in our results might have been confirmed by a larger sample, which could have helped to better explore the impact of COVID-19 on asthma outcomes. However, it seems difficult to design this type of study because of the evolution of the pandemic after vaccination. Among the strengths of this study, it includes many non-vaccinated patients with asthma and COVID infection. To our knowledge, this is the first study with a longitudinal evaluation after at least 6 months from the acute infection, including data from interviews and current physical examinations that others studies do not include [[10]Fernández-de-Las-Peñas C. Torres-Macho J. Velasco-Arribas M. Arias-Navalón J.A. Guijarro C. Hernández-Barrera V. et al.Similar prevalence of long-term post-COVID symptoms in patients with asthma: a case-control study.J. Infect. 2021; 83: 237-279Google Scholar]. In conclusion, patients with severe asthma are at an increased risk of developing long COVID, while eosinophilic and T2-asthma could protect against complications of prolonged COVID.